Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer’s disease

被引：0
|
作者：
Panagiotis Alexopoulos
Lena-Sophie Gleixner
Lukas Werle
Felix Buhl
Nathalie Thierjung
Evangelia Giourou
Simone M. Kagerbauer
Philippos Gourzis
Hubert Kübler
Timo Grimmer
Igor Yakushev
Jan Martin
Alexander Kurz
Robert Perneczky
机构：
[1] Technical University of Munich,Department of Psychiatry and Psychotherapy, Klinikum Rechts der Isar
[2] University Hospital of Rion,Department of Psychiatry
[3] University of Patras,Department of Anaesthesiology, Klinikum Rechts der Isar
[4] Max Planck Institute of Psychiatry,Department of Urology, Klinikum Rechts der Isar
[5] Technical University of Munich,Department of Nuclear Medicine, Klinikum Rechts der Isar
[6] Technical University of Munich,Department of Psychiatry and Psychotherapy
[7] Technical University of Munich,Neuroepidemiology and Ageing Research Unit, Faculty of Medicine, School of Public Health
[8] Ludwig-Maximilians-Universität München,undefined
[9] The Imperial College of Science,undefined
[10] Technology and Medicine,undefined
[11] West London Mental Health NHS Trust,undefined
[12] German Center for Neurodegenerative Diseases (DZNE) Munich,undefined
来源：
European Archives of Psychiatry and Clinical Neuroscience | 2018年 / 268卷
关键词：
Soluble amyloid precursor protein β (sAPPβ); Biomarker-underpinned diagnoses; FDG-PET; Upstream biomarkers; Mild cognitive impairment; Dementia due to Alzheimer’s disease;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The established biomarkers of Alzheimer’s disease (AD) require invasive endeavours or presuppose sophisticated technical equipment. Consequently, new biomarkers are needed. Here, we report that plasma levels of soluble amyloid precursor protein β (sAPPβ), a protein of the initial phase of the amyloid cascade, were significantly lower in patients with symptomatic AD (21 with mild cognitive impairment due to AD and 44 with AD dementia) with AD-typical cerebral hypometabolic pattern compared with 27 cognitively healthy elderly individuals without preclinical AD. These findings yield further evidence for the potential of sAPPβ in plasma as an AD biomarker candidate.
引用
收藏
页码：519 / 524
页数：5
相关论文
共 50 条
  • [21] Advances in the β-amyloid precursor protein of Alzheimer's disease.
    Chen, PL
    Tong, TJ
    Zhang, ZY
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 1999, 26 (02) : 105 - 108
  • [22] The amyloid precursor protein: a converging point in Alzheimer's disease
    Delport, Alexandre
    Hewer, Raymond
    MOLECULAR NEUROBIOLOGY, 2022, 59 (07) : 4501 - 4516
  • [23] Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease
    Anandatheerthavarada, Hindupur K.
    Devi, Latha
    NEUROSCIENTIST, 2007, 13 (06): : 626 - 638
  • [24] Distribution of amyloid β protein precursor in the Alzheimer's disease brain
    Shoji, M
    Kawarabayashi, T
    Matsubara, E
    Ikeda, M
    Ishiguro, K
    Harigaya, Y
    Okamoto, K
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2000, 54 (01) : 45 - 54
  • [25] Amyloid Precursor Protein: A Regulatory Hub in Alzheimer's Disease
    Chen, Jiang
    Chen, Jun-Sheng
    Li, Song
    Zhang, Fengning
    Deng, Jie
    Zeng, Ling-Hui
    Tan, Jun
    AGING AND DISEASE, 2024, 15 (01): : 201 - 225
  • [26] Copper binding to the Alzheimer's disease amyloid precursor protein
    Kong, Geoffrey K. -W.
    Miles, Luke A.
    Crespi, Gabriela A. N.
    Morton, Craig J.
    Ng, Hooi Ling
    Barnham, Kevin J.
    McKinstry, William J.
    Cappai, Roberto
    Parker, Michael W.
    EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS, 2008, 37 (03): : 269 - 279
  • [27] Copper binding to the Alzheimer’s disease amyloid precursor protein
    Geoffrey K.-W. Kong
    Luke A. Miles
    Gabriela A. N. Crespi
    Craig J. Morton
    Hooi Ling Ng
    Kevin J. Barnham
    William J. McKinstry
    Roberto Cappai
    Michael W. Parker
    European Biophysics Journal, 2008, 37 : 269 - 279
  • [28] The amyloid precursor protein: a converging point in Alzheimer’s disease
    Alexandré Delport
    Raymond Hewer
    Molecular Neurobiology, 2022, 59 : 4501 - 4516
  • [29] Amyloid precursor protein, Alzheimer's disease, and Down's syndrome
    Koo, Edward H.
    Alzheimer: 100 Years and Beyond, 2006, : 197 - 199
  • [30] Cholinesterase inhibitors, β-amyloid precursor protein and amyloid β-peptides in Alzheimer's disease
    Lahiri, DK
    Farlow, MR
    Hintz, N
    Utsuki, T
    Greig, NH
    ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 : 60 - 67
12345